
Quarterly report 2024-Q2
added 08-19-2024
Talis Biomedical Corporation Net Debt 2011-2026 | TLIS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Talis Biomedical Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -57.1 M | -96.6 M | -219 M | -138 M | -21.6 M | -6.9 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.9 M | -219 M | -89.8 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Abbott Laboratories
ABT
|
1.65 B | $ 102.58 | -0.28 % | $ 179 B | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.17 | 1.16 % | $ 1.64 B | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
Align Technology
ALGN
|
-925 M | $ 172.16 | 0.91 % | $ 12.9 B | ||
|
Apyx Medical Corporation
APYX
|
3.52 M | $ 3.88 | 5.43 % | $ 159 M | ||
|
Alphatec Holdings
ATEC
|
347 M | $ 10.93 | 0.92 % | $ 1.64 B | ||
|
AxoGen
AXGN
|
15.2 M | $ 33.66 | -2.26 % | $ 1.55 B | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 4.1 | -0.36 % | $ 868 M | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 36.75 | -0.03 % | $ 5.48 K | ||
|
Boston Scientific Corporation
BSX
|
9.26 B | $ 63.21 | 0.62 % | $ 93.6 B | ||
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 9.53 | 1.71 % | $ 270 M | ||
|
CONMED Corporation
CNMD
|
802 M | $ 34.78 | -0.03 % | $ 1.08 B | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.6 | 2.92 % | $ 37.3 M | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 9.72 | 0.88 % | $ 348 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.56 | 5.0 % | $ 133 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 23.59 | 1.29 % | $ 199 M | ||
|
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 81.57 | 0.64 % | $ 47.7 B | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.56 | -0.16 % | $ 122 M | ||
|
NanoVibronix
NAOV
|
-636 K | - | - | $ 1.08 M | ||
|
Globus Medical
GMED
|
-511 M | $ 87.65 | -0.31 % | $ 11.9 B | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.97 | 5.65 % | $ 1.2 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 9.4 | -1.36 % | $ 724 M | ||
|
Inogen
INGN
|
-86.3 M | $ 6.46 | 4.03 % | $ 172 M | ||
|
Inspire Medical Systems
INSP
|
-433 M | $ 56.86 | 3.4 % | $ 1.67 B | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.01 | 3.09 % | $ 17.1 M |